Skip to content

SMMT changes

Pick any two versions below to diff them.

View the full Nov 16, 2026 version
Price
$14.15 → $9.95(−29.7%)
Discount category
Pricey → Below intrinsic value
Thesis
The price of Summit Therapeutics depends almost fully on the results of ivonescimab in global studies and on decisions of the FDA. The HARMONi study in EGFR-mutated lung cancer met its progression-free survival endpoint, but its primary overall survival analysis was not statistically significant, and added: on November 15, 2026 the FDA removed: noted that approval added: rejected the application in this setting removed: needs added: with a removed: significant survival benefit. added: complete response letter. The market values the company on the chance that ivonescimab replaces PD-1 drugs in first-line lung cancer, after studies by Akeso in China showed survival benefits against pembrolizumab and other drugs, and after AstraZeneca invested $2.0 billion in October 2026. For the value to rise, three things must be true. The global HARMONi-3 study must show a clear benefit in first-line squamous lung cancer, with the primary analysis after the needed events in Q4 2026. The FDA must approve ivonescimab in removed: at least one setting. added: another setting, such as first-line lung cancer. Summit must fund its studies without large new share sales. The removed: FDA decision on the HARMONi application, with a goal date of November 14, 2026, and the HARMONi-3 results in 2027 are the next removed: tests. added: test. A negative result can remove most of the value.
Risks
The FDA removed: noted that approval added: rejected the application in EGFR-mutated lung cancer removed: needs a statistically significant overall survival benefit, which added: on November 15, 2026, because the primary analysis of HARMONi did not removed: show. A rejection delays the first sales added: show a statistically significant overall survival benefit. Summit has no approved product in the United removed: States. added: States, and the first sales there now depend on later studies such as HARMONi-3. Summit depends on one drug. If HARMONi-3 or HARMONi-7 fail, most of the value of the company can go. Most positive Phase III data come from studies in China that Akeso ran and analyzed. The FDA can give these data less weight, and limits on trade between the United States and China can affect supply from Akeso. Summit lost $613.5 million in the first nine months of 2026 and pays for its studies by selling shares, and stockholders approved 1 billion more authorized shares. New share sales reduce the part of the company that each share owns. Other companies, many with large drug companies as partners, develop PD-1 and VEGF bispecific antibodies, and pembrolizumab with chemotherapy is the standard treatment in first-line lung cancer.
Checkpoints
Nov removed: 14, added: 15, 2026: FDA decision on HARMONi. removed: Pending. added: Failed. Watch: The FDA approves ivonescimab with chemotherapy in EGFR-mutated lung cancer after TKI therapy, and this passes; a complete response letter fails. added: Outcome: The FDA issued a complete response letter on November 15, 2026, because HARMONi did not show a statistically significant overall survival benefit. Feb 4, 2027 (estimate): Q4 2026 results. Pending. Watch: Cash and investments at December 31, 2026 are more than $2 billion with no large new share sale, and this passes; a large new share sale fails. Q1 2027 (estimate): HARMONi-3 squamous cohort results. Pending. Watch: The squamous cohort of HARMONi-3 shows a statistically significant progression-free survival benefit, and this passes; no significant benefit fails. Q2 2027 (estimate): HARMONi-3 non-squamous cohort results. Pending. Watch: The non-squamous cohort of HARMONi-3 shows a statistically significant progression-free survival benefit, and this passes; no significant benefit fails.
Recent events
Nov added: 15, 2026: The FDA issued a complete response letter for the application to approve ivonescimab with chemotherapy in EGFR-mutated lung cancer after TKI therapy. The FDA said that the progression-free survival benefit of HARMONi, without a statistically significant overall survival benefit, does not give enough evidence of effectiveness for approval. Summit said that it continues its other studies of ivonescimab, including HARMONi-3 and HARMONi-7 in first-line lung cancer. Nov 4, 2026: Summit reported Q3 2026 results. The net loss was $208.4 million, and cash and short-term investments were $629.8 million at September 30, 2026. Stockholders approved an increase of the authorized common shares from 1 billion to 2 billion. Oct 5, 2026: AstraZeneca completed a $2.0 billion equity investment in Class A Convertible Preferred Stock of Summit, convertible into 108,955,369 shares of common stock. In September and October 2026, Summit also agreed to clinical trial collaborations with AstraZeneca, and with AstraZeneca and Daiichi Sankyo, to test ivonescimab with their antibody-drug conjugates. Sep 15, 2026: Updated HARMONi data at WCLC 2026 showed an overall survival hazard ratio of 0.76 in the global population (nominal p=0.0151) and of 0.76 in western patients, with no new safety signals. Sep 2, 2026: Akeso reported that ivonescimab alone improved overall survival against pembrolizumab alone in the HARMONi-2 study in China, with a hazard ratio of 0.73, in PD-L1-positive lung cancer. Aug 25, 2026: Akeso reported that ivonescimab with chemotherapy improved overall survival against durvalumab with chemotherapy in the HARMONi-GI1 study in biliary tract cancer in China. Aug 5, 2026: Summit started HARMONi-GU1, a global Phase II/III study of ivonescimab with enfortumab vedotin in first-line bladder cancer. Jul 23, 2026: Summit reported Q2 2026 results and agreed with J.P. Morgan Securities LLC to sell up to $380 million of common stock through an at-the-market program. May 30, 2026: Phase II data in first-line colorectal cancer at ASCO 2026 showed an objective response rate of 70.8% for ivonescimab with chemotherapy. Jan 29, 2026: The FDA accepted the application to approve ivonescimab with chemotherapy in EGFR-mutated lung cancer after TKI therapy, with a goal date of November 14, 2026.